Helen Torley , , M.B. Ch. B., M.R.C.P. , , President, Chief Executive Officer and member of the Board of Directors

Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-US markets and in particular, in Europe.

Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland.

She received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P). Dr. Torley is a member of the board of directors for Quest Diagnostics. She is also a member of the Health Section Governing Board of BIO, the Biotechnology Innovation Organization, and chair of BIO’s Workforce Development, Diversity and Inclusion committee.

Dimitrios Chondros , , , Senior Vice President, Chief Medical Officer

Dr. Dimitrios Chondros is Senior Vice President and Chief Medical Officer, leading the development of Halozyme’s investigational oncology drug, PEGPH20 and its companion diagnostic assay. Dr. Chondros also oversees translational research efforts to advance understanding of Halozyme’s innovative approach to enzymatically modify the tumor microenvironment. He has broad experience directing complex clinical development and companion diagnostic programs toward global regulatory approvals and preparing for market entry. He joined Halozyme in 2015 as Vice President of Clinical Development, responsible for clinical studies of PEGPH20, including the HALO-301 Phase 3 study in metastatic pancreatic cancer patients.

Dr. Chondros joined Halozyme from Genentech where he held positions of increasing responsibilities in the Product Development Oncology division. He was a member of the Antiangiogenesis and Oncology Signaling Franchise Leadership Teams. As Global Development Team Leader he managed physicians and scientists across global sites as well as cross-functional development teams across several key functions, including clinical science, safety, regulatory affairs, biostatistics, research, biomarkers, clinical pharmacology and clinical operations. For Avastin®, Dr. Chondros was accountable for all global development activities in gastrointestinal cancers, including the label for treatment through multiple lines in metastatic colorectal cancer. He began his industry career at Grünenthal followed by Cell Genesys, where he directed the clinical development of an investigational immunotherapy for prostate cancer. Dr. Chondros has worked for the biopharmaceutical industry in Europe, China and USA.

He is a board certified general surgeon with experience as clinical trial investigator in numerous indications. Dr. Chondros studied medicine at the RWTH Aachen University in Germany and received his M.D. from the University of Zürich, Switzerland.

William J. Fallon , , , Senior Vice President, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances

As Senior Vice President, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances, Mr. Fallon leads Halozyme’s cross-functional team managing strategy and operations for the ENHANZE® business, including direct management of strategic alliances; all aspects of internal and external manufacturing, supply chain, quality assurance, quality control and facilities operations; and bioprocess development. Mr. Fallon joined Halozyme in 2006 as Vice President, Manufacturing & Operations.

Prior to Halozyme, he served as President and Chief Executive Officer of Cytovance Biologics, a contract manufacturing organization that provides manufacturing and development services to the biotechnology industry. From 2001 to 2003, he was Vice President of Technical Operations at Genzyme Corporation, having held the same position at Novazyme Pharmaceuticals, Inc. prior to its acquisition by Genzyme in 2001. Mr. Fallon joined Novazyme from Transkaryotic Therapies, where he was Vice President of Manufacturing from 1998 to 2001. From 1993 to 1998, he was employed in several management positions for the Ares-Serono Group, including Vice President, U.S. Manufacturing Operations. In this role, he served as general manager, overseeing the production and distribution of all of Serono's approved biotechnology products in the U.S. From 1990 to 1992, he was Director of Manufacturing for Centocor, Inc. His prior experience also includes various management and operational roles at Invitron Corporation and Travenol-Genentech Diagnostics. Mr. Fallon earned a B.S. in Marine Science and a B.A. in Biology from Long Island University, and an M.S. in Biology from Northeastern University.

Benjamin J. Hickey , , , Senior Vice President, Chief Commercial Officer

Mr. Benjamin Hickey joined Halozyme in September 2018 as Senior Vice President, Chief Commercial Officer where he is responsible for the global commercial strategy for the company’s current and future oncology portfolio. He joins Halozyme from Bristol-Myers Squibb where he most recently served as the general manager, UK & Ireland overseeing the virology, immuno-science, oncology and cardiovascular disease programs. Throughout his 17-year career with Bristol-Myers Squibb, he held roles of increasing responsibility, including serving as vice president Marketing, Immuno-Oncology where he led the commercialization of Yervoy® and oversaw the launch preparedness of Opdivo® across more than eight indications and executive director and vice president, Hematology, responsible for all commercial activity for Sprycel®, Erbitux® and an investigational multiple myeloma asset. In addition, he served as the U.S. brand lead for Farxiga® which is used to help treat type 2 diabetes. Mr. Hickey earned a Bachelor of Science degree in Sports Management and his MBA from St. Johns University in Queens, New York.

Michael J. LaBarre , , Ph.D. , , Vice President, Chief Scientific Officer

Dr. Michael J. LaBarre has been with Halozyme since 2008 and oversees the research and development of early pipeline assets, product development, and Halozyme’s ENHANZE platform partnerships. Dr. LaBarre brings strong expertise in chemistry, manufacturing and controls (CMC) along with over 23-years of experience across all aspects of biopharmaceutical research and development. In his previous role as Vice President of Product Development at Paramount BioSciences, LLC, Dr. LaBarre led the CMC efforts for all of the product development programs within Paramount’s portfolio companies. Prior to joining Paramount, Dr. LaBarre served in various research and development positions from 1995 to 2006 at Biogen Idec (IDEC from 1995 to 2004), where he had responsibility for analytical and formulation development, protein purification, and physicochemical/biochemical characterization supporting numerous IND and BLA submissions, including those for the commercial products RITUXAN® and ZEVALIN®. His last position with Biogen Idec was Director of Analytical and Protein Biochemistry within the Discovery Research group. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. in the analytical methods development group and he began his career at Hybritech in San Diego, where he held positions in regulatory affairs and manufacturing technical support, focusing on conjugated/radiolabeled antibody technologies and analytical chemistry. Dr. LaBarre received his B.S. in chemistry from Southampton College of Long Island University and his Ph.D. in bioinorganic chemistry from the University of Arizona.

Harry J. Leonhardt , , Esq. , , Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Mr. Leonhardt joined Halozyme in April 2015 as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary. At Halozyme, he is responsible for all legal, compliance and intellectual property matters. Mr. Leonhardt brings more than 30 years of executive management, corporate legal, intellectual property, compliance, business development and mergers and acquisitions experience to Halozyme, with an extensive background in the biotechnology sector. Most recently, he served as Senior Vice President, Legal and Compliance, and Corporate Secretary at Amylin Pharmaceuticals, Inc., a biotech company (acquired by Bristol Myers Squibb in September 2012). Prior to Amylin, he served as Senior Vice President, General Counsel and Corporate Secretary at Senomyx, Inc., Executive Vice President, General Counsel and Corporate Secretary at Genoptix, Inc., and Senior Vice President, General Counsel and Corporate Secretary at Nanogen, Inc. Prior to Nanogen, Mr. Leonhardt held positions of increasing responsibility at Allergan, Inc. including Chief Litigation Counsel and General Counsel for European Operations. Early in his career, he was an attorney at Lyon & Lyon where he represented a number of prominent clients in the biotech, pharmaceutical and consumer products areas. Mr. Leonhardt received a B. Sc. In Pharmacy from the University of the Sciences in Philadelphia and a Juris Doctorate from USC Law School.

Michael E. Paolucci , , , Vice President and Chief Human Resources Officer

Mr. Paolucci joined Halozyme in July 2015 as Vice President and Chief Human Resources Officer, where he is responsible for all aspects of the Company’s human capital strategies, programs, and policies. He brings deep experience as a senior advisor for executive management and Boards of dynamic and fast growing companies. He is also known for developing human capital strategies that are aligned with increasing sustainable shareholder value.

Prior to Halozyme, Mr. Paolucci served as the Executive Vice President, Chief Human Resources Officer for CareFusion. In this role, he was responsible for initiatives to attract, develop and retain employees, company-wide human resource strategy and programs that resulted in sustained improvements in business performance.

Before CareFusion, he served as Executive Vice President of Human Resources at NuVasive, and also spent five years at Life Technologies where he was responsible for global compensation, benefits and HCM systems. He was also head of Human Resources for the services division of Hewlett Packard and served in several leadership roles with EDS, which was acquired by Hewlett Packard. Prior to HP/EDS, he was a partner with the HR consulting firm Towers Perrin. Mr. Paolucci earned his bachelor’s degree in Finance from The Ohio State University.

Laurie D. Stelzer , , , Senior Vice President & Chief Financial Officer

Ms. Laurie Stelzer joined Halozyme in June 2015 as Senior Vice President, Chief Financial Officer where she is responsible for the Finance, Business Development and Information Technology organizations. Prior to joining Halozyme, Ms. Stelzer served as the Senior Vice President of Finance supporting R&D, Technical Operations and M&A at Shire, Inc. Prior to that she was the Division CFO for the Regenerative Medicine Division and the Head of Investor Relations at Shire. Prior to Shire, Ms. Stelzer held positions of increasing responsibility for 15 years at Amgen, Inc. including Interim Treasurer, Head of Emerging Markets Expansion, Executive Director of Global Commercial Finance and Head of Global Accounting. Early in her career, she held various finance and accounting positions in the real estate and banking industries. Ms. Stelzer received her MBA from the Anderson School at the University of California, Los Angeles, and a Bachelor of Science in Accounting from Arizona State University.

Kristina Vlaovic , , , Vice President of Regulatory & Safety

Ms. Vlaovic joined Halozyme in 2015 as Vice President of Regulatory & Safety. Prior to her arrival at Halozyme, she was the global regulatory head for Genentech’s ophthalmology and respiratory franchises. Preceding her experience at Genentech, she has more than 15 years of industry experience at companies such as Amgen, InterMune and Pfizer, leading and implementing strategic regulatory paths for products such as Lucentis®, Enbrel®, Esbriet® and Sutent®, as well as development strategies for numerous Phase 1-3 molecules. Ms. Vlaovic received her BS and MPH from the University of Michigan.

Homa Yeganegi , , , Senior Vice President, Global PEGPH20 Program Lead

As the Global Program Lead for PEGPH20 (pegvorhyaluronidase alfa), Ms. Yeganegi is responsible for the commercialization strategy and operational planning for Halozyme’s investigational new drug, including directing resources from research to development to launch readiness. She joined Halozyme in March 2016 as the Vice President of Global Medical and Scientific Affairs. Ms. Yeganegi has extensive experience in building and leading oncology-focused Global Medical Affairs teams at Clovis Oncology Pharmaceuticals, Exelixis Pharmaceuticals and Onyx Pharmaceuticals. Most recently she was Vice President of Global Medical Affairs at Clovis Oncology Pharmaceuticals where she successfully supported the pre-launch activities for Rociletinib in non-small cell lung cancer in the US and EU. She has a demonstrated track record of success driving strategic data generation, opinion leader development and engagement, scientific strategy and communication including global medical information and scientific education. Ms. Yeganegi has a B. Sc. in Biology from the University of Tehran, Iran, a Master of Science in Neuroanatomy from the University of Western Australia and is completing her Ph.D. in Health Sciences.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.